Nasdaq Espr News Today

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Zacks Research cut their Q4 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Monday, April 29th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will earn $0.14 per share for the quarter, […]

ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following...

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has received a consensus recommendation of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among […]

PSI Advisors LLC lifted its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 161.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,000 shares of the biopharmaceutical company’s stock after purchasing an additional 10,500 shares during the […]

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2026 earnings at $2.50 EPS, FY2027 earnings at […]

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) was the recipient of some unusual options trading on Monday. Investors acquired 11,472 call options on the stock. This represents an increase of approximately 223% compared to the average daily volume of 3,554 call options. Wall Street Analyst Weigh In ESPR has been the subject of several […]

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) saw unusually large options trading activity on Monday. Investors purchased 11,472 call options on the stock. This is an increase of approximately 223% compared to the typical daily volume of 3,554 call options. Analyst Ratings Changes Several brokerages have recently issued reports on ESPR. Bank of America […]

ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) --  Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR (Cholesterol Lowering via...

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Northland Capmk issued their Q1 2024 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Wednesday, February 28th. Northland Capmk analyst C. Byrnes forecasts that the biopharmaceutical company will post earnings per share of ($0.25) for the […]

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03, MarketWatch Earnings reports. The company had revenue of $32.25 million during the quarter, compared to analysts’ expectations of $26.84 million. During the […]